This discovery could lead to a more targeted treatment for patients who carry this mutation. The study is a joint research initiative of MedUni Vienna, Paracelsus Private Medical University in Salzburg and the Medical University of Innsbruck and was initiated and led by MedUni Vienna. The paper has now been published in the specialist journal Cancers. Read more . . .
Although neuroendocrine tumors of the pancreas are rare, the available treatment options are currently limited. Researchers have now managed to identify the mutation mechanism, namely a mutation on the gene that activates the telomerase enzyme TERT, and this will potentially give rise to new treatment options.